Garciaz, Sylvain <br/><br/>
Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.  [electronic resource] 

 -  Leukemia & lymphoma  11 2019 
 - 2802-2805 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.1080/10428194.2019.1599112  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Brentuximab Vedotin--therapeutic use<br/>Combined Modality Therapy<br/>Drug Resistance, Neoplasm<br/>Female<br/>Follow-Up Studies<br/>Hematopoietic Stem Cell Transplantation--methods<br/>Humans<br/>Ki-1 Antigen--metabolism<br/>Lymphoma, Large-Cell, Anaplastic--metabolism<br/>Lymphoma, Non-Hodgkin--metabolism<br/>Lymphoma, T-Cell--metabolism<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--metabolism<br/>Prognosis<br/>Retrospective Studies<br/>Salvage Therapy<br/>Survival Rate<br/>Transplantation, Homologous<br/>Young Adult